Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Alice J. Sigurdson(National Cancer Institute), Neil E. Caporaso(Unknown), Richard B. Hayes(New York University), Jian Gu(Nantong University), Qingyi Wei(Hainan Normal University), Xifeng Wu(Zhejiang Lab), Wen‐Yi Huang(National Institutes of Health), Douglas J. Reding(Ascension), Myron D. Gross(University of Minnesota), Margaret R. Spitz(The University of Texas MD Anderson Cancer Center), Li‐E Wang(The University of Texas MD Anderson Cancer Center), Irene M. Jones(Lawrence Livermore National Laboratory), C. Thomas(Lawrence Livermore National Laboratory), Douglas Stram(National Institutes of Health)
Cited by 24
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k